Unique ID issued by UMIN | UMIN000042853 |
---|---|
Receipt number | R000048898 |
Scientific Title | A randomized, open-label, parallel-group study of the efficacy of oral Ninjin'yoeito in improving fatigability and nutritional status in the perioperative period of primary lung cancer |
Date of disclosure of the study information | 2021/03/01 |
Last modified on | 2021/03/04 10:58:16 |
Efficacy of oral Ninjin'yoeito for improvement of fatigability and nutritional status in the perioperative period of primary lung cancer
Efficacy of oral Ninjin'yoeito in the perioperative period of primary lung cancer
A randomized, open-label, parallel-group study of the efficacy of oral Ninjin'yoeito in improving fatigability and nutritional status in the perioperative period of primary lung cancer
Efficacy of oral Ninjin'yoeito for improvement of fatigability and nutritional status in the perioperative period of primary lung cancer
Japan |
Lung cancer
Chest surgery |
Malignancy
NO
A prospective study will be conducted to evaluate the efficacy of Ninjin'yoeito by administering Ninjin'yoeito in the perioperative period to patients aged 65 years or older who are scheduled for surgery for primary lung cancer, and comparing them with patients in the group that does not receive Ninjin'yoeito to subjectively and objectively evaluate the patients' nutritional status, fatigability, and recovery status.
Efficacy
Chalder Fatigue Scale before administration of Ninjin'yoeito, a month after surgery, and 6 months after surgery.
Cancer Fatigue Scale, Kihon Checklist (KCL), and Controlling nutrition status (COUNT)and Prognostic nutritional index(PNI) before administration of Ninjin'yoeito, a month after surgery, and 6 months after surgery.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
2
Treatment
Medicine |
Three packets of 3.0g (9.0g)of Ninjin'yoeito per day should be taken before or between meals. The dosage should be taken from 2 weeks before to 24 weeks after surgery for primary lung cancer.
Patients do not take Ninjin'yoeito.
65 | years-old | <= |
Not applicable |
Male and Female
1. Patients aged 65 years or older who will undergo anatomical lung resection and systematic lymph node dissection for primary lung cancer at our department.
2. Patients who have given written consent for this study.
3. Patients with primary lung cancer in stages 0, I, II and III.
1. The patient does not give consent to participate in the study.
2.The patient has a history of allergy to Ninjin'yoeito or its components.
3. The patient has severe anorexia, nausea, or vomiting, which is a cautious administration of the study drug.
4. The patient with severe hepatic or renal dysfunction.
200
1st name | Hironori |
Middle name | |
Last name | Ishibashi |
Tokyo Medical and Dental University
Department of Thoracic Surgery, Graduate school of Medical and Dental Sciences
1138510
1-5-45, Yushima, Bunkyo-ku, Tokyo
03-5803-4072
hishiba.thsr@tmd.ac.jp
1st name | Hironori |
Middle name | |
Last name | Ishibashi |
Tokyo Medical and Dental University
Department of Thoracic Surgery, Graduate school of Medical and Dental Sciences
1138510
1-5-45, Yushima, Bunkyo-ku, Tokyo
03-5803-4072
hishiba.thsr@tmd.ac.jp
Tokyo Medical and Dental University
Tokyo Medical and Dental University
Other
Ethics Review Committee, Faculty of Medicine, Tokyo Medical and Dental University
1-5-45, Yushima, Bunkyo-ku, Tokyo
03-5803-5096
syomu1.adm@tmd.ac.jp
NO
2021 | Year | 03 | Month | 01 | Day |
Unpublished
Preinitiation
2021 | Year | 03 | Month | 01 | Day |
2021 | Year | 03 | Month | 01 | Day |
2023 | Year | 12 | Month | 31 | Day |
2020 | Year | 12 | Month | 25 | Day |
2021 | Year | 03 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048898